ASX - By Stock
|
IIQ |
Re:
IIQ Chart
|
|
HomeRun0
|
14 |
8.8K |
0 |
13/07/22 |
13/07/22 |
ASX - By Stock
|
14
|
8.8K
|
0
|
|
ASX - By Stock
|
PNV |
Re:
Ann: Ceasing to be a substantial holder
|
|
HomeRun0
|
19 |
5.6K |
0 |
24/06/22 |
24/06/22 |
ASX - By Stock
|
19
|
5.6K
|
0
|
|
ASX - By Stock
|
PNV |
Re:
Ann: Ceasing to be a substantial holder
|
|
HomeRun0
|
19 |
5.6K |
1 |
24/06/22 |
24/06/22 |
ASX - By Stock
|
19
|
5.6K
|
1
|
|
ASX - By Stock
|
KDY |
Re:
DW8 Growth
|
|
HomeRun0
|
16K |
5.1M |
4 |
16/03/22 |
16/03/22 |
ASX - By Stock
|
16K
|
5.1M
|
4
|
|
ASX - By Stock
|
KDY |
Re:
News: DW8 Dw8 Ltd - Q2 Operating Revenue Grew 78% On Prior Quarter Q1 Fy2022
|
|
HomeRun0
|
69 |
25K |
23 |
08/02/22 |
08/02/22 |
ASX - By Stock
|
69
|
25K
|
23
|
|
ASX - By Stock
|
PNV |
Re:
Ann: 1H22 Indicative Trading Result (unaudited)
|
|
HomeRun0
|
156 |
57K |
2 |
13/01/22 |
13/01/22 |
ASX - By Stock
|
156
|
57K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on BLA for Graft Versus Host Disease
|
|
HomeRun0
|
555 |
268K |
22 |
03/10/20 |
03/10/20 |
ASX - By Stock
|
555
|
268K
|
22
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on BLA for Graft Versus Host Disease
|
|
HomeRun0
|
555 |
268K |
3 |
03/10/20 |
03/10/20 |
ASX - By Stock
|
555
|
268K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Tracking Valuations
|
|
HomeRun0
|
322 |
170K |
3 |
22/09/20 |
22/09/20 |
ASX - By Stock
|
322
|
170K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
HomeRun0
|
13K |
5.0M |
37 |
13/09/20 |
13/09/20 |
ASX - By Stock
|
13K
|
5.0M
|
37
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading - Aug 2020 on
|
|
HomeRun0
|
2.3K |
909K |
7 |
12/08/20 |
12/08/20 |
ASX - By Stock
|
2.3K
|
909K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading - Aug 2020 on
|
|
HomeRun0
|
2.3K |
909K |
8 |
12/08/20 |
12/08/20 |
ASX - By Stock
|
2.3K
|
909K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Ann: COVID-19/GVHD Update, Quarterly Report and Appendix 4C
|
|
HomeRun0
|
248 |
94K |
7 |
31/07/20 |
31/07/20 |
ASX - By Stock
|
248
|
94K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Countdown to Interim Analysis
|
|
HomeRun0
|
195 |
72K |
13 |
17/07/20 |
17/07/20 |
ASX - By Stock
|
195
|
72K
|
13
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
HomeRun0
|
23K |
13M |
7 |
16/05/20 |
16/05/20 |
ASX - By Stock
|
23K
|
13M
|
7
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
HomeRun0
|
23K |
13M |
15 |
14/05/20 |
14/05/20 |
ASX - By Stock
|
23K
|
13M
|
15
|
|
ASX - By Stock
|
MSB |
Re:
COVID-19 ARDS and ARDS Share Price Scenarios
|
|
HomeRun0
|
518 |
265K |
14 |
08/05/20 |
08/05/20 |
ASX - By Stock
|
518
|
265K
|
14
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Phase 2/3 Trial in COVID-19 ARDS Begins Enrollment
|
|
HomeRun0
|
296 |
99K |
6 |
02/05/20 |
02/05/20 |
ASX - By Stock
|
296
|
99K
|
6
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
HomeRun0
|
23K |
13M |
16 |
18/04/20 |
18/04/20 |
ASX - By Stock
|
23K
|
13M
|
16
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
HomeRun0
|
17K |
6.8M |
6 |
12/04/20 |
12/04/20 |
ASX - By Stock
|
17K
|
6.8M
|
6
|
|
ASX - By Stock
|
MSB |
Re:
FDA approved without Randomized Controlled Trial
|
|
HomeRun0
|
52 |
25K |
3 |
05/04/20 |
05/04/20 |
ASX - By Stock
|
52
|
25K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
FDA approved without Randomized Controlled Trial
|
|
HomeRun0
|
52 |
25K |
7 |
05/04/20 |
05/04/20 |
ASX - By Stock
|
52
|
25K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
FDA approved without Randomized Controlled Trial
|
|
HomeRun0
|
52 |
25K |
39 |
04/04/20 |
04/04/20 |
ASX - By Stock
|
52
|
25K
|
39
|
|
ASX - By Stock
|
MSB |
Re:
FDA approved without Randomized Controlled Trial
|
|
HomeRun0
|
52 |
25K |
2 |
04/04/20 |
04/04/20 |
ASX - By Stock
|
52
|
25K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
FDA approved without Randomized Controlled Trial
|
|
HomeRun0
|
52 |
25K |
2 |
02/04/20 |
02/04/20 |
ASX - By Stock
|
52
|
25K
|
2
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
HomeRun0
|
23K |
13M |
7 |
01/04/20 |
01/04/20 |
ASX - By Stock
|
23K
|
13M
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Covid19 watch.
|
|
HomeRun0
|
65 |
24K |
4 |
01/04/20 |
01/04/20 |
ASX - By Stock
|
65
|
24K
|
4
|
|
ASX - By Stock
|
PNV |
Re:
PNV - Chart
|
|
HomeRun0
|
19K |
11M |
2 |
28/03/20 |
28/03/20 |
ASX - By Stock
|
19K
|
11M
|
2
|
|
ASX - By Stock
|
PNV |
Re:
PNV - Chart
|
|
HomeRun0
|
19K |
11M |
1 |
27/03/20 |
27/03/20 |
ASX - By Stock
|
19K
|
11M
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast to Evaluate Remestemcel-L in COVID-19 Lung Disease
|
|
HomeRun0
|
443 |
200K |
4 |
23/03/20 |
23/03/20 |
ASX - By Stock
|
443
|
200K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Change of Director's Interest Notice
|
|
HomeRun0
|
37 |
15K |
8 |
20/03/20 |
20/03/20 |
ASX - By Stock
|
37
|
15K
|
8
|
|
ASX - By Stock
|
PNV |
Re:
Ann: Half Yearly Report and Accounts
|
|
HomeRun0
|
122 |
187K |
0 |
17/03/20 |
17/03/20 |
ASX - By Stock
|
122
|
187K
|
0
|
|
ASX - By Stock
|
PNV |
Re:
Ann: Half Yearly Report and Accounts
|
|
HomeRun0
|
122 |
187K |
4 |
17/03/20 |
17/03/20 |
ASX - By Stock
|
122
|
187K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
HomeRun0
|
17K |
6.8M |
5 |
11/03/20 |
11/03/20 |
ASX - By Stock
|
17K
|
6.8M
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
HomeRun0
|
17K |
6.8M |
2 |
11/03/20 |
11/03/20 |
ASX - By Stock
|
17K
|
6.8M
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast to Evaluate Remestemcel-L in COVID-19 Lung Disease
|
|
HomeRun0
|
443 |
200K |
20 |
10/03/20 |
10/03/20 |
ASX - By Stock
|
443
|
200K
|
20
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
HomeRun0
|
23K |
13M |
14 |
21/02/20 |
21/02/20 |
ASX - By Stock
|
23K
|
13M
|
14
|
|
ASX - By Stock
|
RHK |
Re:
Ann: Invitation - Shareholder Briefings
|
|
HomeRun0
|
105 |
73K |
0 |
20/02/20 |
20/02/20 |
ASX - By Stock
|
105
|
73K
|
0
|
|
ASX - By Stock
|
IIQ |
Re:
Thoughts on BD1?
|
|
HomeRun0
|
25 |
50K |
5 |
13/02/20 |
13/02/20 |
ASX - By Stock
|
25
|
50K
|
5
|
|
ASX - By Stock
|
IIQ |
Re:
Chart
|
|
HomeRun0
|
719 |
588K |
6 |
11/02/20 |
11/02/20 |
ASX - By Stock
|
719
|
588K
|
6
|
|
ASX - By Stock
|
IIQ |
Re:
BARD1 2020
|
|
HomeRun0
|
87 |
58K |
5 |
11/02/20 |
11/02/20 |
ASX - By Stock
|
87
|
58K
|
5
|
|
ASX - By Stock
|
IIQ |
Re:
Chart
|
|
HomeRun0
|
719 |
588K |
4 |
07/02/20 |
07/02/20 |
ASX - By Stock
|
719
|
588K
|
4
|
|
ASX - By Stock
|
PNV |
Re:
PNV - Chart
|
|
HomeRun0
|
19K |
11M |
5 |
07/02/20 |
07/02/20 |
ASX - By Stock
|
19K
|
11M
|
5
|
|
ASX - By Stock
|
PNV |
Re:
PNV - Chart
|
|
HomeRun0
|
19K |
11M |
2 |
07/02/20 |
07/02/20 |
ASX - By Stock
|
19K
|
11M
|
2
|
|
ASX - By Stock
|
PNV |
Re:
$ 3.00 PARTY.
|
|
HomeRun0
|
14 |
11K |
7 |
07/02/20 |
07/02/20 |
ASX - By Stock
|
14
|
11K
|
7
|
|
ASX - By Stock
|
PNV |
Re:
$ 3.00 PARTY.
|
|
HomeRun0
|
14 |
11K |
1 |
07/02/20 |
07/02/20 |
ASX - By Stock
|
14
|
11K
|
1
|
|
ASX - By Stock
|
RMY |
Re:
Ann: RMY joins largest US Real Estate tech accelerator programme
|
|
HomeRun0
|
3 |
2.3K |
2 |
07/02/20 |
07/02/20 |
ASX - By Stock
|
3
|
2.3K
|
2
|
|
ASX - By Stock
|
KDY |
Re:
Competitors?
|
|
HomeRun0
|
5 |
2.4K |
2 |
07/02/20 |
07/02/20 |
ASX - By Stock
|
5
|
2.4K
|
2
|
|
ASX - By Stock
|
KDY |
Re:
Competitors?
|
|
HomeRun0
|
5 |
2.4K |
4 |
07/02/20 |
07/02/20 |
ASX - By Stock
|
5
|
2.4K
|
4
|
|
ASX - By Stock
|
RMY |
Re:
Ann: Significant increase in US Real Estate Agents on RateMyAgent
|
|
HomeRun0
|
30 |
31K |
3 |
06/02/20 |
06/02/20 |
ASX - By Stock
|
30
|
31K
|
3
|
|